阿托伐他汀钙联合辛伐他汀治疗混合型高血脂症的临床观察  

Clinical Observation of Simvastatin Combined with Atorvastatin Calcium in the Treatment of Mixed Hyperlipidemia

作　　者：丁云 张晓萍[2] 欣明花 楼伟建[3] 

机构地区：[1]浙江绿城心血管病医院,杭州310000 [2]杭州民生药业有限公司,杭州310011 [3]浙江大学医学院附属邵逸夫医院,杭州310016

出　　处：《中国药房》2015年第12期1627-1629,共3页China Pharmacy

摘　　要：目的:观察阿托伐他汀钙联合辛伐他汀治疗混合型高血脂症的临床疗效和安全性。方法:78例混合型高血脂症患者随机均分为对照组和观察组。两组患者均给予常规降糖、降血压治疗,同时停用其他降脂药物。在此基础上,对照组患者给予阿托伐他汀钙片20 mg,每晚睡前口服,qd;观察组患者在对照组治疗的基础上给予辛伐他汀片20 mg,每晚睡前口服,qd。两组患者疗程均为8周。观察两组患者的临床疗效,血脂达标率,治疗前后的总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及不良反应发生情况。结果:治疗后观察组患者总有效率、血脂达标率均显著高于对照组,差异均有统计学意义(P<0.05)。治疗后两组患者TG、TC、LDL-C均显著低于同组治疗前,且观察组低于对照组;HDL-C显著高于同组治疗前,且观察组高于对照组(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论:阿托伐他汀钙联合辛伐他汀治疗混合型高血脂症较单用阿托伐他汀钙疗效更显著,安全性相当。OBJECTIVE：To observe the clinical efficacy and safety of atorvastatin calcium combined with simvastatin in the treatment of mixed hyperlipidemia. METHODS：Totally 78 patients with mixed hyperlipidemia were randomly divided into control group and observation group. Two groups of patients were given routine treatment of hypoglycemic and anti-hypertension and stopping other lipid-lowering drugs. Based on it,patients in control group were given Atorvastatin calcium tablets 20 mg;it was taken at bed-time every night,qd. Patients in observation group were given Simvastatin tablets 20 mg based on the treatment of control group;it was orally taken at bed-time every night,qd. The course of both was 8 weeks. The clinical data was observed,including the clinical efficacy,qualified rate of lipid,TC,TG,LDL-C,HDL-C and adverse reactions（ADR）occurrence before and after treatment. RESULTS：The total effective rate and control rate of lipid in observation group were significantly higher than control group,with significant difference（P〈0.05）. After treatment,the TG,TC and LDL-C in 2 groups were significantly lower than before and observation group was lower than control group;HDL-C was significantly higher than before and observation group was higher than control group（P〈0.05）. There was no significant difference in the incidence of adverse reaction（P〉0.05）. CONCLUSIONS：Atorvastatin calcium combined with simvastatin have more significant efficacy than only atorvastatin calcium in the treatment of mixed hyperlipidemia. They have similar safety.

关 键 词：阿托伐他汀钙 辛伐他汀 混合型高血脂症 疗效 安全性 

分 类 号：R559[医药卫生—血液循环系统疾病]